# Alpha Lipoic Acid Cognition Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/alpha-lipoic-acid-cognition-randomized-trial-evidence-review
Category: evidence-review
Summary: Alpha Lipoic Acid Cognition Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pas
Last reviewed: 2026-06-24
Reviewed by: Migaku Evidence Review
# Alpha Lipoic Acid Cognition Randomized Trial: What the Evidence Says

## Quick Answer

Alpha Lipoic Acid Cognition Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives | preclinical study | 4 | 2026-03-26 | 10.3390/neurolint18040064 |

## What The Sources Report

- Neurons, due to their high metabolic activity, limited regenerative capacity, and relatively reduced antioxidant defenses, are particularly vulnerable to disruptions in redox homeostasis and bioenergetic balance. [Aguilera-Méndez Asdrubal (2026); evidence level 4]
- Consequently, strategies targeting mitochondrial function and enhancing antioxidant defenses are of great interest, as alterations in these processes are associated with calcium dysregulation, neuroinflammation, protein misfolding, and neuronal death. [Aguilera-Méndez Asdrubal (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For alpha lipoic acid cognition randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Aguilera-Méndez Asdrubal (2026). Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. DOI: 10.3390/neurolint18040064. PMCID: PMC13118431. PMID: 42042751. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13118431/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.